Yolanda Madarnas

TL;DR: This guideline recommends that patients receiving neoadjuvant anthracycline-taxane-based therapy (or other sequential regimens) whose tumours do not respond to the initial agent or agents, or who experience disease progression, be expedited to the next agent or agent of the regimen.

TL;DR: It is shown that ezrin is expressed at significantly higher levels in lymph node metastases compared to matched primary tumors, and that a high tumor eZrin level is associated with increased risk of relapse in BC patients with regional disease.

TL;DR: A novel function for ezrin is described in the regulation of tumour-induced angio/lymphangiogenesis promoted by Src in breast cancer and the combination of Src/ezrin might prove to be a beneficial prognostic/predictive biomarker for early-stage metastatic breast cancer.

TL;DR: In routine clinical practice, treatment with fec-d is associated with a higher-than-expected rate of febrile neutropenia, in light of which, primary prophylaxis with growth factor should be considered, per international guidelines.